trending Market Intelligence /marketintelligence/en/news-insights/trending/7qltuqkbx_xr6ybfurf7cg2 content esgSubNav
In This List

IMV CEO says 'stressful' part is past; Democrats probe high drug price claims


Japan M&A By the Numbers: Q4 2023


Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


Insight Weekly: Bank mergers of equals return; energy tops S&P 500; green bond sales to rise

IMV CEO says 'stressful' part is past; Democrats probe high drug price claims

Here are the editors' top picks for the week ended July 6.

IMV CEO: 'Stressful' part is past, fundamental year ahead for Canadian biotech

The Canadian biotech's CEO discussed the company's recent data, listing and name change, as well as its looming milestones.

Democrats probe US health chief's blame of middlemen for high drug prices

Two senators are probing recent claims by U.S. Department of Health and Human Services Secretary Alex Azar that drugmakers want to make "substantial and material" price reductions but are being thwarted by middlemen seeking higher rebates.

New clot-busting drugs linked to lower risk of serious bleeding, study shows

Newer anti-clotting drugs such as Bristol-Myers Squibb Co.'s Eliquis cause less risk of a major bleeding episode than warfarin, the oral anticoagulant developed 70 years ago, a new study published in the British Medical Journal showed.

Roche's Tecentriq shows promise against an aggressive breast cancer, study shows

Roche Holding AG said Tecentriq taken in combination with chemotherapy prolonged life and cut the risk of a rare type of breast cancer progressing, marking the third recent win for the immuno-oncology medicine.

Capitol Checkup: US self-inflicted costs; Kentucky blocked; defensive internet

Senators probe what is driving U.S. healthcare costs; court blocks Kentucky Medicaid work requirement; and the Food and Drug Administration's chief said internet companies are helpful, but defensive in the effort to halt online opioid sales.

Novartis to spin off Alcon as CEO continues to streamline, focus on medicines

Novartis AG confirmed plans to spin off its Alcon eye care unit as the new CEO Vas Narasimhan continues to streamline the Swiss pharmaceuticals company and focus on medicines.